major depressive disorder

Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry
Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry
BioSpace
Neurocrine
neuropsychiatric
clinical trials
focal onset seizures
major depressive disorder
NBI-921352
NBI-1065846
Flag link:
Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline
Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline
Fierce Biotech
Novartis
Cadent Therapeutics
major depressive disorder
MIJ821
Flag link:
Exxua Charts a New Path in Depression Treatment Following FDA Nod
Exxua Charts a New Path in Depression Treatment Following FDA Nod
Xtalks
Fabre-Kramer Pharmaceuticals
FDA
Exxua
major depressive disorder
depression
Flag link:
Biomed reports data from trial of MDD therapy
Biomed reports data from trial of MDD therapy
Clinical Trials Arena
BioMed
NA-831
major depressive disorder
clinical trials
Flag link:
Biogen, Sage's postpartum depression approval overshadowed by larger rejection
Biogen, Sage's postpartum depression approval overshadowed by larger rejection
Fierce Pharma
SAGE Therapeutics
Biogen
FDA
Zurzuvae
postpartum depression
major depressive disorder
Flag link:
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Biogen
SAGE Therapeutics
FDA
Zurzuvae
postpartum depression
major depressive disorder
zuranolone
Flag link:
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Flag link:
Go or no go? Biogen and Astellas head towards key PDUFAs
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
Flag link:
9 Highly Anticipated FDA Decisions in Second Half of 2023
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
Flag link:
MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder
MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder
Genetic Engineering News
MindMed
clinical trials
lysergide
LSD
major depressive disorder
Flag link:
Intra-Cellular reports positive Phase III trial of Caplyta in MDD and bipolar depression
Intra-Cellular reports positive Phase III trial of Caplyta in MDD and bipolar depression
Clinical Trials Arena
Intra-Cellular Therapies
clinical trials
Caplyta
major depressive disorder
bipolar disorder
Flag link:
Relmada Looks to Rebound with New Protocol After Two Phase III Flops
Relmada Looks to Rebound with New Protocol After Two Phase III Flops
BioSpace
Relmada Therapeutics
REL-1017
major depressive disorder
Flag link:
FDA says no adcomm planned for Biogen, Sage's depression drug
FDA says no adcomm planned for Biogen, Sage's depression drug
Seeking Alpha
Biogen
SAGE Therapeutics
FDA
zuranolone
major depressive disorder
postpartum depression
Flag link:
Biogen, Sage Get FDA Priority Review of Zuranolone
Biogen, Sage Get FDA Priority Review of Zuranolone
Marketwatch
Biogen
SAGE Therapeutics
FDA
zuranolone
priority review
postpartum depression
major depressive disorder
Flag link:
Small Pharma’s depressive disorder therapy trial meets primary goal
Small Pharma’s depressive disorder therapy trial meets primary goal
Clinical Trials Arena
Small Pharma
clinical trials
SPL026
major depressive disorder
Flag link:
Relmada’s MDD Drug Misses Endpoint, Marred by “Paradoxical Results”
Relmada’s MDD Drug Misses Endpoint, Marred by “Paradoxical Results”
BioSpace
Relmada
REL-1017
major depressive disorder
clinical trials
Flag link:
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
Endpoints
SAGE Therapeutics
Biogen
major depressive disorder
zuranolone
Flag link:
Psychedelics startup nets more than $10M in seed funding as it looks to make a splash
Psychedelics startup nets more than $10M in seed funding as it looks to make a splash
Endpoints
Freedom Biosciences
major depressive disorder
psychedelics
ketamine
FREE001
Flag link:
Praxis wields the axe as lead depression drug fails
Praxis wields the axe as lead depression drug fails
Pharmaforum
Praxis Precision Medicines
major depressive disorder
layoffs
restructuring
PRAX-114
Flag link:
Sage, Biogen get rolling on FDA submission for depression med
Sage, Biogen get rolling on FDA submission for depression med
Fierce Biotech
SAGE Therapeutics
Biogen
zuranolone
FDA
major depressive disorder
Flag link:

Pages